IDCRC Newsletter: July 2025

Spotlight: "Enterovirus" Study Principal Investigator

This month, we are excited to spotlight Elizabeth AD Hammershaimb, MD, MS, the principal investigator of the IDCRC study, "Phase 1, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of an Enterovirus D68-specific Monoclonal Antibody in Healthy Adults." This phase 1 study is assessing the safety and pharmacokinetics of EV68-228-N, a monoclonal antibody against enterovirus D68 (EV-D68).

Elizabeth AD Hammershaimb, MD, MS

Dr. Hammershaimb is an assistant professor of pediatric infectious diseases at the University of Maryland School of Medicine. Her research focuses on clinical trials in children and adults; vaccines against biothreat agents, emerging infections, and malaria; vaccine hesitancy and acceptance; pediatric infectious diseases; and antimicrobial stewardship.

"The human relationships facilitated by the IDCRC network are invaluable. Being part of IDCRC has not only allowed me to build relationships with peers around the country but also provided access to mentors at other institutions. It helps to step outside of our respective bubbles and connect with people who work on similar topics but with different populations and in different environments," shares Dr. Hammershaimb.

READ HAMMERSHAIMB'S SPOTLIGHT

Expert Working Groups

New Expert Working Group Members

The Leadership Operations Center (LOC) recently conducted biannual Expert Working Group (EWG) rotations for our early career investigators. Congratulations to the following IDCRC members!

Early career members who transitioned to full voting members:

Enteric EWG:

Elizabeth AD Hammershaimb, University of Maryland

Emerging EWG

Daniel Graciaa, Emory University
Brett Jagger, Saint Louis University (SLU)

Malaria & Tropical Diseases EWG

Angelica Kottkamp, New York University (NYU)

Respiratory EWG

Erin Nicholson, Baylor University
Tia Babu, University of Washington (UW)

Third Cohort MCDC members who joined as early career members:

Emerging EWG

Lauren Jatt, UW
Andrew Fleming, NYU

Respiratory EWG

Daniel Graciaa, Emory
Cristina Tomatis-Souverbielle, University of Cincinnati (CCHMC)

STI EWG

Thinzar Wei, Univeristy of Rochester
Nina Prasanphanich, CCHMC
Cassie Grimsley-Ackerly, Emory

Thank you departing EWG members!

Thank you to the following early career investigators for the two-year term with the following EWGs. We appreciate your service and contributions to the IDCRC's mission and goals.

Emerging EWG

Stephanie Rolsma, Vanderbilt University
Dan Croft, Rochester

Enteric EWG

Lalitha Parameswaran, NYU
Hannah Bahakel, CCHMC
Paulina Rebolledo, Emory

Malaria & Tropical Diseases EWG

Katia Bruxvoort, University of Alabama at Birmingham

Respiratory EWG

Zacharoula Oikonomopoulou, SLU
Christopher Palma, Rochester
Satoshi Kamidani, Emory

STI EWG

Chase Cannon, UW

Secondary Research

Learn about Secondary Research Resources & Information

Have you had a chance to check out the IDCRC's new webpage on the website dedicated to Secondary Research? If not, be sure to head to our website for an overview of the following topics:

Specimen/data request process
Available specimens
Terms of approval
Study implementation

SECONDARY RESEARCH WEBPAGE

Training

MCDC Mentoring Lecture Series

The IDCRC Mentoring Lecture Series brings the IDCRC mentees together with leading experts to discuss topics related to the VTEUs, vaccinology, and clinical trials development and management. Check out our recent lecture below!

IDCRC MCDC Lecture Series: Global Health

Global Health: Where Science Meets Humanity

Presenter:
Karen Kotloff, MD
PI, University of Maryland School of Medicine Vaccine and Treatment Evaluation Unit

VIEW FULL ARCHIVE

News

IDSA Media Briefing | Impact of HHS COVID-19 Vaccine Recommendations

Flor Munoz-Rivas, MD, FIDSA (Baylor), was selected to speak in the Infectious Diseases Society of America Media Briefing. These experts discussed the public health implications of the Department of Health and Human Services’ COVID-19 vaccination guidelines.

Traditional processes for federal vaccine recommendations
What the latest recommendations mean for patients and clinicians
Vaccine access

LISTEN HERE

Impact of HHS COVID-19 Vaccine Recommendations

Emory Daily Pulse | New NIH-Funded Program to Uncover How Flu Spreads Through the Air

Nadine Rouphael, MD, Emory VTEU principal investigator, is among a team of researchers who recently received P01 NIAID funding to study the transmission of influenza. She will serve as the principal investigator of the clinical core on this study.

The program will bring together expertise in virology, immunology, aerosol science, and mathematical modeling to generate a high-resolution picture of flu transmission. The insights gained are expected to guide more targeted interventions—such as vaccines, ventilation strategies, and masking recommendations—grounded in a stronger understanding of how the virus truly spreads.

Job Postings

Newly Posted! Infectious Diseases Research Job Openings

Visit the IDSA Career Center to browse other ID/HIV Medicine job postings.

Funding Opportunities

Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)
Deadline: Thursday, October 16, 2025

Notice of Special Interest (NOSI): Complement in Fundamental Immunology
Deadline: Tuesday, January 7, 2026

Advancing Research Needed to Develop a Coccidioidomycosis (Valley fever) Vaccine
Deadline: Thursday, January 15, 2026

Notice of Special Interest (NOSI): Using Targeted Degradation of Protein and non-Protein Targets for the Development of Novel Anti-Infectives
Deadline: Friday, July 17, 2026

Notice of Special Interest (NOSI): Promoting Research and Development of Vaccines Against Enteric Viruses *New*
Deadline: Friday, July 17, 2026

Notice of Special Interest (NOSI): Research to Stimulate Development of Diagnostics, Therapeutics, and Vaccines for Herpes Simplex Virus (HSV)
Deadline: Wednesday, April 6, 2027

Notice of Special Interest (NOSI): Systems Modeling of Infection and Immunity Across Biological Scales
Deadline: Wednesday, September 8, 2027

Notice of Special Interest (NOSI): Advancing Research Needed to Develop a Universal Influenza Vaccine
Deadline: Sunday, November 17, 2027

Notice of Special Interest (NOSI): Accelerating Malaria Vaccine and Monoclonal Antibody Discovery *New*
Deadline: Sunday, November 17, 2027

IDCRC Studies

Active Studies
Recruiting Volunteers

A Randomized, Double-Blind, Placebo-Controlled Phase 1 Trial to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of Sanaria(R) PfSPZ-LARC2 Vaccine, a Late-Arresting, Replication-Competent, Genetically Attenuated Plasmodium Falciparum Vaccine by Controlled Human Malaria Infection in Malaria-Naïve Healthy Adults
Conditions (DMID 23-0010)
Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults (DMID 23-0006)
A Phase 4 Study of a 3-Day vs. 7-Day Regimen of Doxycycline for the Treatment of Chlamydial Infection (DMID 22-0019)

Fully Enrolled Studies
in Follow-up

A Phase 1 Trial to Evaluate the Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine, HydroVax-001B WNV in Healthy Adults (DMID 24-0008)
Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine (DMID 22-0020A)
A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety and Pharmacokinetics of a Single Ascending Dose of EV-D68-228 in Healthy Adult Volunteers (DMID 23-0005)
A Prospective, Randomized, Open-label Phase 4 Study of the Immunology and Safety of Maternal RSV Vaccination (ABRYSVOTM), Infant Nirsevimab (BEYFORTUSTM) Immunization, or Both Products During the First Year of Life (PROMISE) (DMID 24-0003)